Illustratively, we have shown that the in situ vaccine effect of EBRT was enhanced when combined with tumor-targeted hu14.18-IL2 immunocytokine injections [15], yet in the presence of multiple tumors, the same combination therapy targeted to a single tumor was ineffective [16]. The gene discussed is IL2; the disease is neoplasm.